Article Versions Notes

Li T, Liu L, Li L, Yao X, Hu X, Cheng J, Chen Z, Guo J, Li R, Ge C, et al. HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma. Pharmaceuticals. 2024; 17(5):645. https://doi.org/10.3390/ph17050645

Li, Tao, Ling Liu, Li Li, Xiaoxuan Yao, Xiaoyuan Hu, Jiaxing Cheng, Zhenpu Chen, Jiyin Guo, Ruilei Li, Chunlei Ge, and et al. 2024. "HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma" Pharmaceuticals 17, no. 5: 645. https://doi.org/10.3390/ph17050645

Li, T., Liu, L., Li, L., Yao, X., Hu, X., Cheng, J., Chen, Z., Guo, J., Li, R., Ge, C., Lin, M. C. -M., & Yao, H. (2024). HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma. Pharmaceuticals, 17(5), 645. https://doi.org/10.3390/ph17050645